Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Awada, Ahmad; Colomer, Rámón; Inoue, Kenichi; Bondarenko, Igor; Badwe, Rajendra; Demetriou, Georgia; Chin Lee, Soo; Mehta, Ajay; Kim, Sung‐Bae; Bachelot, Thomas; Goswami, Chanchal; V.S. Deo, Suryanarayan; Bose, Ron; Wong, Alvin; Xu, Feng; Yao, Bin; Bryce, Richard; A. Carey, Lisa

doi:10.1001/jamaoncol.2016.0237

Public

Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer

Published in JAMA Oncology • Apr 14, 2016

Authors:

Ahmad Awada

Rámón Colomer

Kenichi Inoue

Abstract

IMPORTANCE: Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. OBJECTIVE: To determine whether neratinib, an irreversible pan-ERBB tyrosine kinase inhibitor, plus paclitaxel improves progression-free survival compared with trastuz...

Subject

Medicine

Trastuzumab

Lapatinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!